Development and Characterization of Lyophilized Chondroitin Sulfate-Loaded Solid Lipid Nanoparticles: Encapsulation Efficiency and Stability

dc.contributor.authorBustos Araya, Marta Eduviges
dc.contributor.authorNardi Ricart, Anna
dc.contributor.authorCalpena Campmany, Ana Cristina
dc.contributor.authorProhens López, Rafael
dc.contributor.authorMiñarro Carmona, Montserrat
dc.date.accessioned2026-07-24T09:30:39Z
dc.date.available2026-07-24T09:30:39Z
dc.date.issued2025-01-10
dc.date.updated2026-07-24T09:30:40Z
dc.description.abstractThis study explores the development and characterization of lyophilized chondroitin sulfate (CHON)-loaded solid lipid nanoparticles (SLN) as an innovative platform for advanced drug delivery. Background/Objectives: Solid lipid nanoparticles are increasingly recognized for their biocompatibility, their ability to encapsulate diverse compounds, their capacity to enhance drug stability, their bioavailability, and their therapeutic efficacy. Methods: CHON, a naturally occurring glycosaminoglycan with anti inflammatory and regenerative properties, was integrated into SLN formulations using the hot microemulsion technique. Two formulations (SLN-1 and SLN-2) were produced and optimized by evaluating critical physicochemical properties such as particle size, zeta potential, encapsulation efficiency (EE%), and stability. The lyophilization process, with the addition of various cryoprotectants, revealed trehalose to be the most effective agent in maintaining nanoparticle integrity and functional properties. Results: Morphological analyses using transmission electron microscopy (TEM) and atomic force microscopy (AFM) confirmed the dimensions of the nanoscales and their structural uniformity. Differential scanning calorimetry (DSC) and X-ray diffraction (XRD) revealed minimal excipient interaction with CHON, ensuring formulation stability. Stability studies under different environmental conditions highlighted that SLN-2 is the most stable formulation, maintaining superior encapsulation efficiency (≥88%) and particle size consistency over time. Conclusions: These findings underscore the potential of CHON-loaded SLNs as promising candidates for targeted, sustained-release therapies in the treatment of inflammatory and degenerative diseases.
dc.format.extent24 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec753763
dc.identifier.issn1999-4923
dc.identifier.pmid39861734
dc.identifier.urihttps://hdl.handle.net/2445/230993
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/pharmaceutics17010086
dc.relation.ispartofPharmaceutics, 2025, vol. 17, num.86
dc.relation.urihttps://doi.org/10.3390/pharmaceutics17010086
dc.rightscc-by (c) Bustos Araya, Marta Eduviges et al., 2025
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
dc.subject.classificationMicroscòpia electrònica de transmissió
dc.subject.classificationNanopartícules
dc.subject.classificationMicroscòpia de força atòmica
dc.subject.classificationLípids
dc.subject.otherTransmission electron microscopy
dc.subject.otherNanoparticles
dc.subject.otherAtomic force microscopy
dc.subject.otherLipids
dc.titleDevelopment and Characterization of Lyophilized Chondroitin Sulfate-Loaded Solid Lipid Nanoparticles: Encapsulation Efficiency and Stability
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
877023.pdf
Mida:
8.85 MB
Format:
Adobe Portable Document Format